[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=13c13c910cedd44ec5dd4b47db926ab353fe4422d8071b0a6821600df1f728e6",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747154220,
      "headline": "Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
      "id": 134440773,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=13c13c910cedd44ec5dd4b47db926ab353fe4422d8071b0a6821600df1f728e6"
    }
  },
  {
    "ts": null,
    "headline": "2 Biotech Stocks That Are Screaming Buys in May",
    "summary": "Two biotech stocks make perfect candidates for this sort of strategy right now.  Let's take a close look at these two biotech stocks that are screaming buys in May.  The launch and revenue growth processes take longer for such a product than for standard medicines because gene editing involves several steps.",
    "url": "https://finnhub.io/api/news?id=31e57692a73a06d31807afe8974a8dcee4c4b4d431273c7ad41ccd4fb06e172c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747134600,
      "headline": "2 Biotech Stocks That Are Screaming Buys in May",
      "id": 134409181,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Two biotech stocks make perfect candidates for this sort of strategy right now.  Let's take a close look at these two biotech stocks that are screaming buys in May.  The launch and revenue growth processes take longer for such a product than for standard medicines because gene editing involves several steps.",
      "url": "https://finnhub.io/api/news?id=31e57692a73a06d31807afe8974a8dcee4c4b4d431273c7ad41ccd4fb06e172c"
    }
  },
  {
    "ts": null,
    "headline": "This Stock Just Dropped by 12% in 1 Day. History Says This Will Happen Next",
    "summary": "Vertex Pharmaceuticals' shares dropped due to poor first-quarter results.  Vertex's business and prospects remain attractive.  Vertex Pharmaceuticals (NASDAQ: VRTX), a leading drugmaker, is performing exceedingly well for the year -- or at least it was, until it released its first-quarter update.",
    "url": "https://finnhub.io/api/news?id=1eb7081a038586943a795d7031a9e8294c86c3bb9ce73555f0fc4270b8914008",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747126320,
      "headline": "This Stock Just Dropped by 12% in 1 Day. History Says This Will Happen Next",
      "id": 134409184,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals' shares dropped due to poor first-quarter results.  Vertex's business and prospects remain attractive.  Vertex Pharmaceuticals (NASDAQ: VRTX), a leading drugmaker, is performing exceedingly well for the year -- or at least it was, until it released its first-quarter update.",
      "url": "https://finnhub.io/api/news?id=1eb7081a038586943a795d7031a9e8294c86c3bb9ce73555f0fc4270b8914008"
    }
  }
]